Aims: The aim was to compare the anticancer and antimutagenic potency of Polyalthia cerasoides seeds and stem bark.
Aim Of The Study: The aim of this study was to investigate the antiproliferative, apoptotic, antioxidation to DNA, and antimutagenic activity of alcoholic (PS-1 and PS-3) and petroleum ether (PS-2 and PS-4) stem bark and seed fractions of P. cerasoides.
Methods: P. cerasoides stem bark and seeds were extracted with ethanol: water mixture (9:1 ratio v: v) and fractionated with petroleum ether. Fractions were investigated for antiproliferative effect using cell by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, a tetrazole assay (cell line used liver [HepG2] and cervical [HeLa] cancer cell lines), DNA damage protection using hydroxyl radical and antimutagenic effect using chromosome aberration test.
Results: PS-1 (IC50 10 μg/ml) and PS-3 (IC50 11 μg/ml) showed maximum antiproliferative activity against HepG2 cell lines, whereas, PS-1 (IC50 10 μg/ml), PS-2 (IC50 24 μg/ml), and PS-3 (IC50 11 μg/ml) showed better antiproliferative activity against HeLa cell lines. PS-3 and PS-4 were protective against oxidation to the supercoiled DNA molecule. Further, petroleum ether extract of both seed (PS-2) and stem bark (PS-4) showed good antimutagenicity as revealed by the less chromosomal aberrations compared to PS-1 and PS-3 fractions.
Conclusions: This study demonstrated the beneficial effect of fractions against oxidation of DNA, antiproliferative, apoptotic, and antimutagenic activity. Probably, this property would be attributable by their phenolic and steroid constituents. Therefore, this plant could be used as a potential source of nutraceutical agents.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/jcrt.JCRT_1170_19 | DOI Listing |
Heliyon
September 2024
Human Resources Office, Guangxi Medical University, Nanning, 530002, China.
Objective: Recent studies reveal that necroptosis is pivotal in tumorigenesis, cancer metastasis, cancer immunity, and cancer subtypes. Apoptosis or necroptosis of hepatocytes in the liver microenvironment can determine the subtype of liver cancer. However, necroptosis-related genomes have rarely been analyzed in hepatocellular carcinoma (HCC).
View Article and Find Full Text PDFContext: Kidney renal clear-cell carcinoma (KIRC) is a malignant tumor. At an early stage, KIRC patients may experience only mild fever and fatigue or even no symptoms, and these early nonspecific indications can delay treatment. Neurotransmitters and their receptors may be very useful in determining tumorigenesis and predicting metastasis.
View Article and Find Full Text PDFFront Cell Dev Biol
July 2023
Department of Orthopedics, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical, Taizhou, Zhejiang, China.
Overexpression of the gene has been linked with tumor progression, aggressiveness, drug resistance, and poor patient prognosis. Most research has described the biological function of the in certain types and limited samples, but a comprehensive understanding of the 's function and clinical importance at the pan-cancer level is scarce. More research is needed to understand the role of in tumor infiltration, and immune checkpoint inhibitors in various cancers are needed.
View Article and Find Full Text PDFA novel geldanamycin derivative LZY3016 was synthesized as an antitumor agent. Compound LZY3016 exhibited potent anti-proliferation activity toward MDA-MB-231 (IC = 0.06 μM), which was more effective than positive drug 17-AAG.
View Article and Find Full Text PDFJ Enzyme Inhib Med Chem
December 2022
School of Life and Pharmaceutical Sciences, Dalian University of Technology, Panjin, China.
The molecular chaperone HSP90 plays an essential role in cancer occurrence and development. Therefore, it is an important target for the development of anticancer drugs. 1,3-Dibenzyl-2-aryl imidazolidine ( is a previously reported inhibitor of HSP90; however, its anticancer activity is poor.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!